Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea.

Sang Hyun ParkYoung Ju ChoiEun Jung RheeKab Bum Huh

Published in: Endocrinology and metabolism (Seoul, Korea) (2020)

Treatment with DAPA, whether added to or switched from other glucose-lowering agents, significantly decreased HbA1c levels in Korean patients with type 2 diabetes who visited a single primary diabetes clinic. DAPA can be considered as an optimal second-line treatment for patients with type 2 diabetes, as supported by real-world evidence studies.

Keyphrases

type diabetes
primary care
cardiovascular disease
combination therapy
skeletal muscle
replacement therapy